iBio Expands Development and Mfg. Capacity

iBio CMO LLC, a subsidiary of iBio, Inc., a provider of plant-based biotechnology for developing and manufacturing biologics, has completed the expansion of product development capacity for the production of pharmaceutical proteins in hydroponically-grown green plants.

This expansion enables the use iBio technologies to conduct concurrent product development work for clients in multiple product classes with transitions from lab-level feasibility and testing through cGMP production of active pharmaceutical ingredients for toxicology studies and Phase I clinical trials.

“An important consideration for many of our clients and prospective clients is our ability to save them time during critical stages of their proprietary product development programs,” said Dr. Barry Holtz, iBio’s senior vice president of product development and manufacturing. “We can provide definitive technical answers faster than conventional mammalian cell-based systems and then move directly into larger scale production. This avoids engineering and reengineering mammalian cell lines and dealing with the scale-up issues associated with traditional CHO cell production.”